GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 397
- Registration Number
- NCT00486018
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 613
- Registration Number
- NCT00485589
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00480831
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Withdrawn
- Conditions
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00477425
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT00476996
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Center For Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Arthritis Consultants, Saint Louis, Missouri, United States
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT00473382
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00473590
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT00473330
Study of Cobimetinib in Participants With Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT00467779
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT00453362
© Copyright 2024. All Rights Reserved by MedPath